09.05.13
BioReliance, the biologics and early-development services business under SAFC, has opened a new Clearance Services facility in Rockville, MD. The facility, commissioned on August 1, 2013, allows BioReliance to offer increased capacity, flexible scheduling, and more than doubles the amount of space to conduct critical downstream bioprocessing studies.
The Rockville facility features four large clearance suites with modular layouts for customized laboratory setups. According to the company, all studies are secure and supported by dedicated scientists and chromatography equipment, such as GE Healthcare’s ÄKTA avant, as well as fully compliant with applicable global guidelines and regulations, including the FDA and EMA.
“Combining our deep knowledge and proven experience with a global investment in modern facilities and equipment enables BioReliance to offer robust validation packages and proprietary CompleteClearance™ services to our clients. It’s all about simplifying the viral clearance process through an unrivaled combination of scientific expertise, client-focused service and decades of experience,” said Archie Cullen, president of BioReliance. “Any time a client comes to work with us, they are assured that their study is expertly designed and performed by personnel that have participated in thousands of successful studies in support of clinical and commercial biopharmaceutical products.”
The Rockville facility features four large clearance suites with modular layouts for customized laboratory setups. According to the company, all studies are secure and supported by dedicated scientists and chromatography equipment, such as GE Healthcare’s ÄKTA avant, as well as fully compliant with applicable global guidelines and regulations, including the FDA and EMA.
“Combining our deep knowledge and proven experience with a global investment in modern facilities and equipment enables BioReliance to offer robust validation packages and proprietary CompleteClearance™ services to our clients. It’s all about simplifying the viral clearance process through an unrivaled combination of scientific expertise, client-focused service and decades of experience,” said Archie Cullen, president of BioReliance. “Any time a client comes to work with us, they are assured that their study is expertly designed and performed by personnel that have participated in thousands of successful studies in support of clinical and commercial biopharmaceutical products.”
